Latest Biotechnology News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.